

# **STRATEC Biomedical Systems AG**

**Interim Report as of September 30, 2006**

Dear Shareholders,

We informed you in our interim report as of June 30, 2006 that we would be updating our new guidance figures. The updated figures have since been published.

The highly pleasing course of business to date in 2006 and the ongoing increase in customer sales forecasts, which are in some cases of a binding and in others of a non-binding nature, and in particular in the forecasts provided by our largest customer, enabled us to substantially raise the guidance figures compared with the previously valid set of figures.

According to the forecast published on September 7, 2006, we assume that it will be possible to increase our sales for the 2006 financial year to between Euro 65 million and Euro 68 million (previously: Euro 55 million to Euro 60 million) and to generate earnings before tax (EBT) of between Euro 10.5 million and Euro 11 million (previously: Euro 8.3 million to Euro 9.2 million).

The increase in the forecast for the 2006 financial year has now been corroborated by our nine-month figures.

In the first nine months of the 2006 financial year, the STRATEC Group had an average of 215 employees and generated sales of Euro 51.9 million. This is equivalent to an increase of 53% compared with the previous year. At Euro 5.3 million, consolidated net income was 83% higher than the equivalent figure for the previous year. Following adjustment for the capital increase undertaken from company funds and the related issue of bonus shares, earnings per share therefore amounted to Euro 0.48 (previous year: Euro 0.29).


Although many German second-line stocks, even those of companies with highly promising performances, have suffered setbacks in the difficult market climate for second-line stocks in recent months, it is pleasing to note that our share has been listed close to its all-time high, even reaching new all-time highs in recent days. Over and above this, we have observed a further increase in the interest shown in our company by German and international investors.

Birkenfeld, November 2006


The Board of Management of  
STRATEC Biomedical Systems AG



Hermann Leistner



Marcus Wolfinger



Bernd M. Steidle

## Events between July and September 2006

- The updated version of our Company Brochure was published in July 2006. We would be pleased to send you a copy upon request. The brochure can also be downloaded from our homepage at "Investor Relations" > "Download" and then in the "Miscellaneous" section.
- The capital increase of Euro 7,416,478.00 from company funds resolved by the Annual General Meeting of STRATEC Biomedical Systems AG on June 23, 2006 was entered in the Commercial Register on July 14, 2006.

The shareholders in the company were entitled to receive bonus shares on their previous shareholdings at a ratio of 1 : 1.9942188, meaning that 1.9942188 additional new shares (bonus shares) were allocated for each share previously held. The new shares will participate for the first time in the profit for the 2006 financial year.

The allocation of bonus shares to shareholders was undertaken starting on July 31, 2006 by means of a credit to their securities accounts based on their securities account holdings on the evening of July 28, 2006. The allocation procedure has now been completed. Since July 31, 2006, the bonus shares have been included in the company's current listing.

- At the beginning of September, we published our new sales and earnings forecasts for the 2006 and 2007 financial years in an ad-hoc announcement and those for the 2008 to 2010 financial years in a press release. We raised our previous budgeted level of sales and earnings in view of the pleasing order situation, the enhancements to our product portfolio and of benefits of scale and degression effects.

This forecast expects sales to increase in the 2006 financial year to between Euro 65 million and Euro 68 million (sales corridor) and earnings before tax (EBT) to rise more rapidly than sales, reaching between Euro 10.5 million and Euro 11 million (earnings corridor).

Our forecast for the 2007 financial year provides for sales growth to between Euro 75 million and Euro 78 million (sales corridor) and growth in earnings before tax (EBT) to between Euro 14 million and Euro 15 million (earnings corridor).

From 2008 up to and including 2010, we expect to achieve annual average growth rates (CAGR) of more than 11% in the case of sales and of more than 16% for earnings before tax (EBT).

Please also see the extensive information published in this respect on September 7, 2006, which is also available on our homepage.

## **Employees**

The STRATEC Group had a total of 215 employees as of September 30, 2006 (previous year: 189).

## **Our forecast model**

Within the framework of long-term development and supply contracts, our customers provide us at regular intervals with forecasts for various periods in the future. While one part of such forecasts constitutes a legally binding order, the other assists us in our planning and accounts for the forecasting reliability in the business model of STRATEC.

## **Investments**

In the first nine months of the 2006 financial year, STRATEC invested a total of EUR 360k in property, plant and equipment (previous year: EUR 1,226k) and EUR 93k in software (previous year: EUR 128k). Moreover, STRATEC invested a total of EUR 5,515k in financial assets in the first nine months of 2006 (previous year: EUR 759k), of which EUR 1,650k related to long-term third-party securities (previous year: EUR 665k) and EUR 3,865k to shares in affiliated companies (previous year: EUR 65k). This figure includes the cash holdings of EUR 1,209k (previous year: EUR 0k) at the acquired company Sanguin.

## **Research and development expenses**

The expenses relating to research and project management, and to development services not fulfilling the capitalization criteria set out in IAS 38, amounted to Euro 5,580k in the first nine months (previous year: Euro 3,757k) and have been reported mainly as personnel expenses in the company's consolidated income statement. Moreover, procurement volumes of around Euro 479k (previous year: Euro 467k) were incurred during the period under report in connection with materials used in research and development. These have been included in the cost of materials item.

## **Inclusion of Sanguin in the consolidated financial statements**

Pursuant to IFRS 3 (Business Combinations) the consolidated income statement of the STRATEC Group for the second and third quarters of 2006 includes the income statement of Sanguin, a company acquired in March.

In contrast to the balance sheet, which has been consolidated with effect from the first quarter of 2006, the aforementioned accounting regulation only permits the figures of the profitable company Sanguin for the second and third quarters to be included in the consolidation of the income statement for the first nine months.

# Facts and Figures

## Consolidated Balance Sheet (in Euro 000s)

| <b>Assets</b>                             | <b>09.30.2006</b> | <b>12.31.2005</b> |
|---|-------------------|-------------------|
| <b>A. Fixed assets</b>                    |                   |                   |
| Intangible assets                         | 4,640             | 188               |
| Goodwill                                  | 860               | -                 |
| Property, plant and equipment             | 5,464             | 5,688             |
| Financials assets                         | 3,054             | 840               |
|   | <b>14,018</b>     | <b>6,716</b>      |
| <b>B. Current assets</b>                  |                   |                   |
| Raw materials and supplies                | 5,755             | 4,167             |
| Unfinished products, unfinished services  | 9,055             | 8,566             |
| Accounts receivable                       | 9,531             | 10,495            |
| Future receivables from production orders | 5,228             | 3,115             |
| Other assets                              | 1,492             | 489               |
| Other securities                          | 578               | -                 |
| Cash on hand, cash at banks               | 8,321             | 9,962             |
|   | <b>39,960</b>     | <b>36,794</b>     |
| <b>C. Prepayments and accrued income</b>  | <b>235</b>        | <b>117</b>        |
| <b>Total assets</b>                       | <b>54,213</b>     | <b>43,627</b>     |

| <b>Shareholders' equity and liabilities</b>       | <b>09.30.2006</b> | <b>12.31.2005</b> |
|---|-------------------|-------------------|
| <b>A. Shareholders' equity</b>                    |                   |                   |
| Share capital                                     | 11,203            | 3,660             |
| Capital reserve                                   | 9,668             | 15,896            |
| Revenue reserves                                  | 11,178            | 7,567             |
| Consolidated net earnings                         | 5,304             | 4,413             |
| Treasury stock                                    | -13               | -13               |
|   | <b>37,340</b>     | <b>31,523</b>     |
| <b>B. Dept capital</b>                            |                   |                   |
| <b>1. Long-term debt capital</b>                  |                   |                   |
| Provisions for pensions                           | 24                | 24                |
| Provisions for deferred taxes                     | 2,072             | 394               |
| Long-term financial liabilities                   | 1,604             | 1,706             |
|   | <b>3,700</b>      | <b>2,124</b>      |
| <b>2. Short-term debt capital</b>                 |                   |                   |
| Short-term financial liabilities                  | 1,129             | 1,840             |
| Accounts payable                                  | 5,087             | 2,463             |
| Liabilities to affiliated companies               | -                 | 57                |
| Short-term provisions                             | 2,475             | 1,547             |
| Tax provisions                                    | 525               | 2,319             |
| Other short-term liabilities                      | 3,957             | 1,754             |
|   | <b>13,173</b>     | <b>9,980</b>      |
| <b>Total shareholders' equity and liabilities</b> | <b>54,213</b>     | <b>43,627</b>     |

## Consolidated Income Statement (in Euro 000s)

|  | 07.01.06 - 09.30.06 | 07.01.05 - 09.30.05 |
|--|---------------------|---------------------|
| <b>Sales</b>                                 | <b>19,260</b>       | <b>10,805</b>       |
| Increase in unfinished products and services | 84                  | 535                 |
| Other capitalized own-account services       | 41                  | 59                  |
| <b>Overall performance</b>                   | <b>19,385</b>       | <b>11,399</b>       |
| Other operating income                       | 77                  | 19                  |
| Cost of raw materials and supplies           | -11,587             | -5,770              |
| Cost of services rendered                    | -204                | -247                |
| Personnel expenses                           | -3,252              | -2,843              |
| Other operating expenses                     | -1,706              | -934                |
| <b>EBITDA</b>                                | <b>2,713</b>        | <b>1,624</b>        |
| Depreciation of fixed assets                 | -415                | -269                |
| <b>EBIT</b>                                  | <b>2,298</b>        | <b>1,355</b>        |
| Net interest expenses                        | -33                 | -82                 |
| <b>Result of ordinary activities (EBT)</b>   | <b>2,265</b>        | <b>1,273</b>        |
| Current taxes                                | -585                | -166                |
| Deferred taxes                               | 76                  | -178                |
| <b>Consolidated net income</b>               | <b>1,756</b>        | <b>929</b>          |

|                           |               |                 |
|---------------------------|---------------|-----------------|
| <b>Earnings per share</b> | <b>€ 0.16</b> | <b>€ 0.09 *</b> |
| No. of underlying shares  | 11,165,284    | 9,970,497 *     |

|                                    |               |                 |
|------------------------------------|---------------|-----------------|
| <b>Earnings per share, diluted</b> | <b>€ 0.52</b> | <b>€ 0.37 *</b> |
| No. of underlying shares           | 11,365,237    | 10,284,800 *    |

\* Due to the execution of the capital increase from company funds in July 2006 (factor: 2.9942188) the number of shares used in the calculation of "earnings per share" has been adjusted in the interests of comparability.

## Consolidated Income Statement (in Euro 000s)

|  | 01.01.06 - 09.30.06 | 01.01.05 - 09.30.05 |
|--|---------------------|---------------------|
| <b>Sales</b>   | <b>51,933</b>       | <b>33,945</b>       |
| Reduction (previous year: increase)<br>in unfinished products and services | -171                | 1,508               |
| Other capitalized own-account services                                     | 125                 | 129                 |
| <b>Overall performance</b>   | <b>51,887</b>       | <b>35,582</b>       |
| Other operating income   | 273                 | 114                 |
| Cost of raw materials and supplies   | -29,389             | -18,462             |
| Cost of services rendered  | -508                | -585                |
| Personnel expenses   | -9,365              | -8,406              |
| Other operating expenses   | -4,603              | -2,929              |
| <b>EBITDA</b>  | <b>8,295</b>        | <b>5,314</b>        |
| Depreciation of fixed assets   | -1,096              | -728                |
| <b>EBIT</b>  | <b>7,199</b>        | <b>4,586</b>        |
| Net interest expenses  | -102                | -178                |
| <b>Result of ordinary activities (EBT)</b>                                 | <b>7,097</b>        | <b>4,408</b>        |
| Current taxes  | -1,559              | -1,347              |
| Deferred taxes   | -234                | -167                |
| <b>Consolidated net income</b>   | <b>5,304</b>        | <b>2,894</b>        |

|                           |               |                 |
|---------------------------|---------------|-----------------|
| <b>Earnings per share</b> | <b>€ 0.48</b> | <b>€ 0.29 *</b> |
| No. of underlying shares  | 11,059,426    | 9,913,191 *     |

|                                    |               |                 |
|------------------------------------|---------------|-----------------|
| <b>Earnings per share, diluted</b> | <b>€ 0.47</b> | <b>€ 0.28 *</b> |
| No. of underlying shares           | 11,346,176    | 10,226,521 *    |

\* Due to the execution of the capital increase from company funds in July 2006 (factor: 2.9942188) the number of shares used in the calculation of "earnings per share" has been adjusted in the interests of comparability.

## Consolidated Cash Flow Statement (in Euro 000s)

|   | 01.01.06 - 09.30.06 | 01.01.05 - 09.30.05 |
|---|---------------------|---------------------|
| Consolidated net income   | 5,304               | 2,894               |
| Deprecation of fixed assets   | 1,096               | 728                 |
| Other expenses not affecting payments   | 147                 | 99                  |
| Decrease in long-term provisions  | -                   | -4                  |
| Increase in provisions for deferred taxes   | 234                 | 167                 |
| <b>Cash flow</b>  | <b>6,781</b>        | <b>3,884</b>        |
| Profit from disposals of fixed assets   | -27                 | -20                 |
| Increase in inventories, accounts receivable and other assets   | -4,436              | -6,633              |
| Increase in accounts payable and other liabilities  | 2,541               | 2,971               |
| <b>Inflow of funds from operating activities</b>  | <b>4,859</b>        | <b>202</b>          |
| Incoming payments from disposals of fixed assets  | 33                  | 20                  |
| Addition of cash and cash equivalents resulting from change in reporting entity   | 1,209               | -                   |
| Investment in company acquisition   | -3,769              | -                   |
| Outgoing payments for investments in fixed assets   | -2,194              | -1,522              |
| <b>Outflow of funds from investment activities</b>  | <b>-4,721</b>       | <b>-1,502</b>       |
| Dividend payments   | -1,351              | -660                |
| Outgoing payments (previous year: incoming payments) from the repayment (previous year: taking up) of (financial) loans | -866                | 876                 |
| Incoming payments from the capital increase   | 438                 | 11,911              |
| <b>Outflow of funds (previous year: inflow of funds) from financing activities</b>                                      | <b>-1,779</b>       | <b>12,127</b>       |
| <b>Payment-related change in financial funds</b>  | <b>-1,641</b>       | <b>-10,827</b>      |
| Financial funds at start of period  | 9,962               | 1,222               |
| <b>Financial funds at end of period</b>   | <b>8,321</b>        | <b>12,049</b>       |



## Statement of Changes in Group Shareholders' Equity (in Euro 000s)

| January - September 2005                          | Subscribed capital | Capital reserve | Revenue reserves | Consolidated net income | Treasury stock | Total equity  |
|---|--------------------|-----------------|------------------|-------------------------|----------------|---------------|
| <b>Balance at 01.01.2005</b>                      | <b>3,300</b>       | <b>4,059</b>    | <b>5,344</b>     | <b>2,778</b>            | <b>-13</b>     | <b>15,468</b> |
| Capital increase in return for cash contributions | 330                | 11,627          | -                | -                       | -              | 11,957        |
| Capital increase due to share option plans        | 30                 | 66              | -                | -                       | -              | 96            |
| Transfer due to share option plans                | -                  | 99              | -                | -                       | -              | 99            |
| Dividend payment                                  | -                  | -               | -660             | -                       | -              | -660          |
| Profit carried forward                            | -                  | -               | 2,778            | -2,778                  | -              | -             |
| Consolidated net income                           | -                  | -               | -                | 2,894                   | -              | 2,894         |
| <b>Balance at 09.30.2005</b>                      | <b>3,660</b>       | <b>15,851</b>   | <b>7,462</b>     | <b>2,894</b>            | <b>-13</b>     | <b>29,854</b> |

| January - September 2006  | Subscribed capital | Capital reserve | Revenue reserves | Consolidated net income | Treasury stock | Total equity  |
|---|--------------------|-----------------|------------------|-------------------------|----------------|---------------|
| <b>Balance at 01.01.2006</b>  | <b>3,660</b>       | <b>15,896</b>   | <b>7,567</b>     | <b>4,413</b>            | <b>-13</b>     | <b>31,523</b> |
| Profit carried forward  | -                  | -               | 4,413            | -4,413                  | -              | -             |
| Capital increase from company funds   | 7,416              | -7,416          | -                | -                       | -              | -             |
| Dividend payment  | -                  | -               | -1,351           | -                       | -              | -1,351        |
| Capital increase for company acquisition by issuing 18,206 shares   | 18                 | 782             | -                | -                       | -              | 800           |
| Capital increase in return for cash contributions in the course of the exercising of 63,190 share options | 109                | 312             | -                | -                       | -              | 421           |
| Transfer due to share option plans  | -                  | 94              | -                | -                       | -              | 94            |
| Adjustment resulting from the valuation of assets available for sale at fair value                        | -                  | -               | 549              | -                       | -              | 549           |
| Consolidated net income   | -                  | -               | -                | 5,304                   | -              | 5,304         |
| <b>Balance at 09.30.2006</b>  | <b>11,203</b>      | <b>9,668</b>    | <b>11,178</b>    | <b>5,304</b>            | <b>-13</b>     | <b>37,340</b> |

## Breakdown of Sales at the Group

The breakdown of sales into their respective geographical regions represents the distribution of STRATEC products. In view of the fact that the customers of STRATEC generally supply their country outlets and customers from central distribution centers, however, this breakdown of sales does not represent the geographical distribution of the final operating locations of STRATEC analyzer systems. We assume that the overwhelming majority, with a rising tendency, of all analyzer systems ever produced by STRATEC are now located outside Germany.

Sales can be broken down into their respective geographical regions (customer locations) as follows:

| Period                   | Germany  | EU        | Other    | Total     |
|--------------------------|----------|-----------|----------|-----------|
| January - September 2005 | € 8,285k | € 20,089k | € 5,571k | € 33,945k |
|                          | 24.4%    | 59.2%     | 16.4%    | 100.0%    |

| Period                   | Germany   | EU        | Other    | Total     |
|--------------------------|-----------|-----------|----------|-----------|
| January - September 2006 | € 10,114k | € 36,440k | € 5,379k | € 51,933k |
|                          | 19.5%     | 70.2%     | 10.4%    | 100.0%    |

**Disclosures on the volume of treasury stock in STRATEC Biomedical Systems AG and on the subscription rights of members of the company's executive and supervisory bodies and of its employees pursuant to Section 160 (1) Nos. 2 and 5 of the German Stock Corporation Act (AktG)**

As of September 30, 2006, STRATEC Biomedical Systems AG owned a total of 4,492 of its own shares. This corresponds to a prorated amount of Euro 4,492 of its share capital and to a 0.04% share in its equity.

In view of the several "conditional capitals" created by resolutions adopted at the Annual General Meetings held on July 27, 2000, May 28, 2003 and June 23, 2006, these various items have been combined below in the interests of clarity.

The members of the Board of Management and the employees held the following numbers of subscription rights (share option rights) as of September 30, 2006:

| <b>Conditional Capital I / II / III</b> | <b>Board of Management</b> | <b>Employees</b> | <b>Total</b>   |
|---|----------------------------|------------------|----------------|
| <b>Outstanding on 06.30.2006</b>        | <b>37,500</b>              | <b>74,856</b>    | <b>112,356</b> |
| Issued                                  | 9,370                      | 15,630           | 25,000         |
| Expired                                 | -                          | 22,546           | 22,546         |
| Lapsed                                  | -                          | -                | -              |
| <b>Outstanding on 09.30.2006</b>        | <b>46,870</b>              | <b>67,940</b>    | <b>114,810</b> |

## Outlook

The outsourcing of automation solutions by our clients represents more than just a trend. The clients which sell STRATEC automation solutions as system solutions together with their own reagents to laboratories and blood banks around the world thereby cede their competencies concerning the economic development and production of automation solutions in total or in part. This development is mainly a result of our clients focusing on their respective core competencies, the development of reagents (chemicals companies) and their approval, as well as of clients focusing on the completion of their product portfolios (completeness of the relevant tests) and the expansion of their own market presence. The resultant outsourcing requirements continue to provide STRATEC with very good, increasing opportunities for growth.

Our growth ambitions are supported by factors such as the launch of new systems onto the market, as well as by a focus on the revision of systems already on the market in terms of expanding their functionalities. At the same time, these factors represent one of the key challenges facing development departments, given the volatility of production margins. Having mainly focused in the first nine months of this year on expanding our production and development capacities, we are currently concentrating on logistical measures enabling us to offset fluctuations in production capacity utilization rates.

Further company growth is to be expected in the medium to long term.

## Latest News

- Within the framework of STRATEC's trade fair activities, a team of employees attended the "AABB Annual Meeting", an annual meeting of the AABB (American Association of Blood Banks) held in Miami Beach, Florida, USA, at the end of October 2006, as well as the TXPO fair held at the same time. These events provided an opportunity for more than 6,000 specialists and decision makers from the fields of blood banks and transfusion medicine to come together.
- The "Deutsches Eigenkapitalforum" event organized by Deutsche Börse AG and KfW Mittelstandsbank will take place in Frankfurt am Main from November 27 to November 29, 2006. As Europe's largest and most successful equity financing platform, this year's Forum will build on the success of events in previous years and aims once again in the current year to provide companies financed by private equity and publicly listed companies with the opportunity of presenting themselves to the capital market under the motto of "Entrepreneurs Meet Investors".

STRATEC will be holding its annual analysts' conference within the framework of this Forum on November 29, 2006, thus presenting itself to numerous industry analysts, investors and business journalists. In particular, the company will provide detailed information on its performance figures as of September 30, 2006 and on the latest developments.

- "MEDICA 2006", the world's leading specialist medical fair, will take place at the Düsseldorf Exhibition Center from November 15 to November 18, 2006. As the world's largest specialist medical congress, MEDICA provides all professional interested parties with a comprehensive overview of all facets of the medical market.

STRATEC will be represented with a booth in Hall 3 (Stand D 72). Our employees will be available to answer any questions you may have.

At the MEDICA fair, STRATEC will focus once again this year on the business-to-business meetings held in parallel to the fair.

Together with the AACC (American Association for Clinical Chemistry), which was held in Chicago, Illinois, USA, from July 23 to July 27, 2006, MEDICA, the world's largest medical congress, is the most important business-to-business event for STRATEC.

- The "WestLB Deutschland Conference 2006" will be held in Frankfurt am Main on November 15 and November 16, 2006 with a focus on "Sustaining profitable growth".

The WestLB Deutschland Conference provides an individual communications platform for international investors and publicly listed German companies.

Within the framework of the conference, on November 16, 2006 the company will be outlining how the STRATEC Group is implementing its strategy for achieving sustainable profitable growth.

## Notice

This interim report is also available in German.

The interim report as of September 30, 2006 has been compiled in accordance with IAS 34. Application has been made of the total cost method in the compilation of the interim report as of September 30, 2006. Unless otherwise stated, the same accounting and valuation methods have been used as in the previous annual financial statements. The accounting and valuation methods applied therein have been presented in detail in the notes to the annual financial statements as of December 31, 2005.

Pursuant to IAS 34.16, only those aspects which relate to STRATEC have been disclosed in the text of the quarterly report.

Consolidation principles – Receivables and liabilities between the companies consolidated have been offset against one another. The same applies to inter-company income and expenses. The financial assets of STRATEC Biomedical Systems AG have also been consolidated with the share capital of Robion AG and Sanguin International Ltd. The various currencies have been converted using period-end exchange rates. Reference is made to IAS 34.16 in respect of the remaining items in the notes.

For reasons of comparability, the figures of Robion AG for the previous year have been adjusted to the existing reporting entity. This has resulted in insubstantial variances to the figures published in the interim report as of September 30, 2005. As a result of the acquisition of Sanguin International Ltd., the figures stated in the balance sheet are only comparable to a limited extent.

Forward-looking statements involve risks. This interim report contains various statements concerning the future performance of STRATEC. These statements are based both on assumptions and on estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

There may be some discrepancies throughout this interim report on account of mathematical rounding up in the course of addition.

Anglicisms in the field of diagnostics – The specialist terminology used in the field of diagnostics mainly derives from linguistic usage in the English-speaking world. For this reason, we make periodic use of “anglicisms” in our ongoing reporting. Any attempt to find a suitable German equivalent for these established terms relating to diagnostics could result in an impediment of the concepts in question. We nevertheless take trouble to define such concepts in German wherever we consider it feasible.

## Financial Calendar 2006/2007

|               |  |
|---------------|--|
| 11.16.2006    | WestLB Deutschland Conference,<br>Frankfurt am Main  |
| 11.29.2006    | Deutsches Eigenkapitalforum –<br>Frankfurt am Main   |
| 01.15.2007    | 6th German Corporate Conference,<br>Frankfurt am Main<br>(Organizer: Cheuvreux, Deutschland) |
| April 2007    | Annual results telephone conference  |
| 05.09.2007    | Publication of 3 month report  |
| 05.16.2007    | Annual General Meeting, Pforzheim  |
| 08.08.2007    | Publication of 6 month report  |
| 11.07.2007    | Publication of 9 month report  |
| November 2007 | Deutsches Eigenkapitalforum –<br>Frankfurt am Main   |

Partially incomplete / Subject to amendment

## About STRATEC

STRATEC Biomedical Systems AG (<http://www.stratec-biomedical.de>) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such system solutions, in general together with their own reagents, to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. The shares in the company (WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard market segment of the Frankfurt Stock Exchange and in the Gate-M trading segment of the Stuttgart Stock Exchange, as well as on other exchanges.

The STRATEC Group comprises the listed holding company "STRATEC Biomedical Systems AG" and the subsidiaries "STRATEC NewGen", "Robion" and "Sanguin".

Regularly updated information about the company can be found at our website at: [www.stratec-biomedical.de](http://www.stratec-biomedical.de).

**STRATEC Biomedical Systems AG**

**Gewerbestr. 37**

**75217 Birkenfeld**

**Germany**

**Tel: +49 7082 7916-0**

**Fax: +49 7082 7916-999**

**[ir@stratec-biomedical.de](mailto:ir@stratec-biomedical.de)**

**[www.stratec-biomedical.de](http://www.stratec-biomedical.de)**

**stratec<sup>®</sup>●●**  
biomedical systems